Derek K Ng1, Lisa P Jacobson, Todd T Brown, Frank J Palella, Jeremy J Martinson, Robert Bolan, Edgar R Miller, George J Schwartz, Alison G Abraham, Michelle M Estrella. 1. aDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health bDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland cDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois dGraduate School of Public Health, Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania eLos Angeles Gay and Lesbian Center, Los Angeles, California fWelch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland gDepartment of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.
Abstract
OBJECTIVE: Diabetes and hypertension, common conditions in antiretroviral-treated HIV-infected individuals, are associated with glomerular hyperfiltration, which precedes the onset of proteinuria and accelerated kidney function decline. In the Multicenter AIDS Cohort Study, we examined the extent to which hyperfiltration is present and associated with metabolic, cardiovascular, HIV and treatment risk factors among HIV-infected men. DESIGN: Cross-sectional cohort using direct measurement of glomerular filtration rate by iohexol plasma clearance for 367 HIV-infected men and 241 HIV-uninfected men who were free of chronic kidney disease. METHODS: Hyperfiltration was defined as glomerular filtration rate above 140-1 ml/min per 1.73 m per year over age 40. Multivariate logistic regression was used to estimate the odds ratios (ORs) of prevalent hyperfiltration for metabolic, cardiovascular, HIV and cumulative antiretroviral exposure factors. RESULTS: Among individuals without chronic kidney disease, the prevalence of hyperfiltration was higher for HIV-infected participants (25%) compared to uninfected participants (17%; P = 0.01). After adjustment, HIV infection remained associated with hyperfiltration [OR 1.70, 95% confidence interval (CI) 1.11-2.61] and modified the association between diabetes and hyperfiltration, such that the association among HIV-uninfected men (OR 2.56, 95% CI 1.33-5.54) was not observed among HIV-infected men (OR 1.19, 95% CI 0.69-2.05). These associations were independent of known risk factors for hyperfiltration. Indicators of hyperglycemia and hypertension were also associated with hyperfiltration as was cumulative zidovudine exposure. CONCLUSION: Hyperfiltration, a potential modifiable predictor of kidney disease progression, is significantly higher among antiretroviral-treated HIV-infected men. Furthermore, HIV-infection nullifies the association of diabetes and hyperfiltration present in HIV-uninfected men.
OBJECTIVE:Diabetes and hypertension, common conditions in antiretroviral-treated HIV-infected individuals, are associated with glomerular hyperfiltration, which precedes the onset of proteinuria and accelerated kidney function decline. In the Multicenter AIDS Cohort Study, we examined the extent to which hyperfiltration is present and associated with metabolic, cardiovascular, HIV and treatment risk factors among HIV-infectedmen. DESIGN: Cross-sectional cohort using direct measurement of glomerular filtration rate by iohexol plasma clearance for 367 HIV-infectedmen and 241 HIV-uninfectedmen who were free of chronic kidney disease. METHODS: Hyperfiltration was defined as glomerular filtration rate above 140-1 ml/min per 1.73 m per year over age 40. Multivariate logistic regression was used to estimate the odds ratios (ORs) of prevalent hyperfiltration for metabolic, cardiovascular, HIV and cumulative antiretroviral exposure factors. RESULTS: Among individuals without chronic kidney disease, the prevalence of hyperfiltration was higher for HIV-infectedparticipants (25%) compared to uninfected participants (17%; P = 0.01). After adjustment, HIV infection remained associated with hyperfiltration [OR 1.70, 95% confidence interval (CI) 1.11-2.61] and modified the association between diabetes and hyperfiltration, such that the association among HIV-uninfectedmen (OR 2.56, 95% CI 1.33-5.54) was not observed among HIV-infectedmen (OR 1.19, 95% CI 0.69-2.05). These associations were independent of known risk factors for hyperfiltration. Indicators of hyperglycemia and hypertension were also associated with hyperfiltration as was cumulative zidovudine exposure. CONCLUSION: Hyperfiltration, a potential modifiable predictor of kidney disease progression, is significantly higher among antiretroviral-treated HIV-infectedmen. Furthermore, HIV-infection nullifies the association of diabetes and hyperfiltration present in HIV-uninfectedmen.
Authors: Leslie A Bruggeman; Michael D Ross; Nozomu Tanji; Andrea Cara; Steven Dikman; Ronald E Gordon; Godfrey C Burns; Vivette D D'Agati; Jonathan A Winston; Mary E Klotman; Paul E Klotman Journal: J Am Soc Nephrol Date: 2000-11 Impact factor: 10.121
Authors: A M Caliendo; A Valsamakis; Y Zhou; B Yen-Lieberman; J Andersen; S Young; A Ferreira-Gonzalez; G J Tsongalis; R Pyles; J W Bremer; N S Lurain Journal: J Clin Microbiol Date: 2006-05 Impact factor: 5.948
Authors: Christina M Wyatt; Susan Morgello; Rebecca Katz-Malamed; Catherine Wei; Mary E Klotman; Paul E Klotman; Vivette D D'Agati Journal: Kidney Int Date: 2008-12-03 Impact factor: 10.612
Authors: Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Daniel Bertenthal; Paul A Volberding; Ann M O'Hare Journal: J Am Soc Nephrol Date: 2007-10-17 Impact factor: 10.121
Authors: Kristine M Erlandson; Derek K Ng; Lisa P Jacobson; Joseph B Margolick; Adrian S Dobs; Frank J Palella; Jordan E Lake; Hanhvy Bui; Lawrence Kingsley; Todd T Brown Journal: J Infect Dis Date: 2017-01-15 Impact factor: 5.226
Authors: Robert C Kalayjian; Kunling Wu; Scott Evans; David B Clifford; Muraldihar Pallaki; Judith S Currier; Marlene Smryzynski Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Julie A Womack; Terrence E Murphy; Linda Leo-Summers; Jonathan Bates; Samah Jarad; Alexandria C Smith; Thomas M Gill; Evelyn Hsieh; Maria C Rodriguez-Barradas; Phyllis C Tien; Michael T Yin; Cynthia A Brandt; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2022-10-01 Impact factor: 3.771
Authors: Alison G Abraham; Annie Darilay; Heather McKay; Joseph B Margolick; Michelle M Estrella; Frank J Palella; Robert Bolan; Charles R Rinaldo; Lisa P Jacobson Journal: J Infect Dis Date: 2015-03-11 Impact factor: 5.226
Authors: Flávia Vanesca Felix Leão; Regina Célia de Menezes Succi; Daisy Maria Machado; Aída de Fátima Thomé Barbosa Gouvêa; Fabiana Bononi do Carmo; Suenia Vasconcelos Beltrão; Maria Aparecida de Paula Cançado; João Tomas de Abreu Carvalhaes Journal: Pediatr Nephrol Date: 2015-12-04 Impact factor: 3.714
Authors: Gregory M Lucas; Mohamed G Atta; Katie Zook; Allison M McFall; Shruti H Mehta; Derek M Fine; James H Stein; George J Schwartz Journal: AIDS Date: 2016-02-20 Impact factor: 4.177